Memantine Augmentation in Obsessive-Compulsive Disorder

Completed · Phase 1/Phase 2

Conditions studied: Obsessive-Compulsive Disorder

In brief

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Key facts

Study ID

NCT00264238

Run by

Stanford University

People needed

15

Starts

2006-01-01

Expected to finish

2008-06-01

Last updated by the study team

2017-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• at least 18 years of age
• suffering from OCD
• Y-BOCS score of 18 or greater
• taking a therapeutic dose of an anti-OCD medication specified in the protocol

You may not qualify if…

• diagnosed with a mental disorder other than OCD
• taking tiagabine or pregabalin
• having had a previous trial of memantine
• receiving therapy for OCD
• substance abuse in the last 6 months
• personality disorders sufficiently severe to interfere with study participation

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.